Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19212942 | 0.88 | CHRNB2 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL18157905 | 0.81 | ALDH1A1 (0.32) | BRD4BRD9ALDH1A1HTR2AHTR2C | |
| SCHEMBL18516701 | 0.78 | CYP19A1 (0.35) | ALDH1A1 | |
| SCHEMBL2512278 | 0.76 | — | — | |
| SCHEMBL12849515 | 0.75 | CHRNB2 (0.33) | CHRNB2CHRNA4 | |
| SCHEMBL15180076 | 0.75 | HTR1A (0.35) | ALDH1A1HTR2A | |
| SCHEMBL8269744 | 0.74 | — | — | |
| SCHEMBL13702951 | 0.72 | PDE10A (0.37) | CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL15193798 | 0.72 | PIK3CG (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL24248776 | 0.71 | CHRNB2 (0.33) | CHRNB2CHRNA4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020200154-A1 | A CLASS OF THIOPHENE FUSED N-HETEROCYCLIES, PREPARATION METHOD AND USE | 上海凌达生物医药有限公司 | 2020-10-08 | — | — | WO | disclosed |
| WO-2012052420-A1 | METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES | MERCK SERONO S.A. GENEVA (CH) | 2012-04-26 | — | — | WO | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | PFKP, PDXK, PF4 | CHRNB2 2180/4885CHRNA4 1685/4885BRD4 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.